Fluticasone propionate/formoterol fumarate in fixed-dose combination for the treatment of asthma

David Price, Elizabeth V Hillyer

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

A new combination inhaler containing fluticasone, a potent inhaled corticosteroid (ICS), and formoterol, a long-acting β-agonist (LABA) with rapid onset and sustained bronchodilator effect, has been approved for treatment of persistent asthma in patients ≥12 years of age requiring combination ICS-LABA therapy. The fluticasone/formoterol combination, delivered via pressurized metered-dose inhaler and available in three dose strengths, has demonstrated a good safety and tolerability profile in trials of up to 1 year. The efficacy of fluticasone/formoterol is greater than that of fluticasone or formoterol alone and noninferior to that of fluticasone/salmeterol and budesonide/formoterol in tightly controlled 8-12-week clinical trials. Advantages of the fluticasone/formoterol combination aerosol include rapid onset of bronchodilation, an attribute preferred by patients, and emission of a high fine-particle fraction that is consistent at different flow rates, which may aid consistency of delivery (given patient variability in inhalation maneuvers) and provide real-life benefits.

Original languageEnglish
Pages (from-to)275-291
Number of pages17
JournalExpert Review of Respiratory Medicine
Volume8
Issue number3
DOIs
Publication statusPublished - Jun 2014

Fingerprint

Asthma
Adrenal Cortex Hormones
Metered Dose Inhalers
Budesonide
Nebulizers and Vaporizers
Bronchodilator Agents
Therapeutics
Aerosols
Inhalation
Clinical Trials
Safety
Fluticasone
flutiform
Formoterol Fumarate

Keywords

  • anti-inflammatory
  • asthma
  • bronchodilator
  • fluticasone propionate
  • formoterol fumarate
  • inhaled corticosteroid
  • long-acting ß-agonist

Cite this

Fluticasone propionate/formoterol fumarate in fixed-dose combination for the treatment of asthma. / Price, David; Hillyer, Elizabeth V.

In: Expert Review of Respiratory Medicine, Vol. 8, No. 3, 06.2014, p. 275-291.

Research output: Contribution to journalArticle

@article{b24a46c066ee45d79ec94c0675080f0b,
title = "Fluticasone propionate/formoterol fumarate in fixed-dose combination for the treatment of asthma",
abstract = "A new combination inhaler containing fluticasone, a potent inhaled corticosteroid (ICS), and formoterol, a long-acting β-agonist (LABA) with rapid onset and sustained bronchodilator effect, has been approved for treatment of persistent asthma in patients ≥12 years of age requiring combination ICS-LABA therapy. The fluticasone/formoterol combination, delivered via pressurized metered-dose inhaler and available in three dose strengths, has demonstrated a good safety and tolerability profile in trials of up to 1 year. The efficacy of fluticasone/formoterol is greater than that of fluticasone or formoterol alone and noninferior to that of fluticasone/salmeterol and budesonide/formoterol in tightly controlled 8-12-week clinical trials. Advantages of the fluticasone/formoterol combination aerosol include rapid onset of bronchodilation, an attribute preferred by patients, and emission of a high fine-particle fraction that is consistent at different flow rates, which may aid consistency of delivery (given patient variability in inhalation maneuvers) and provide real-life benefits.",
keywords = "anti-inflammatory , asthma, bronchodilator, fluticasone propionate, formoterol fumarate, inhaled corticosteroid, long-acting {\ss}-agonist",
author = "David Price and Hillyer, {Elizabeth V}",
year = "2014",
month = "6",
doi = "10.1586/17476348.2014.905914",
language = "English",
volume = "8",
pages = "275--291",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - Fluticasone propionate/formoterol fumarate in fixed-dose combination for the treatment of asthma

AU - Price, David

AU - Hillyer, Elizabeth V

PY - 2014/6

Y1 - 2014/6

N2 - A new combination inhaler containing fluticasone, a potent inhaled corticosteroid (ICS), and formoterol, a long-acting β-agonist (LABA) with rapid onset and sustained bronchodilator effect, has been approved for treatment of persistent asthma in patients ≥12 years of age requiring combination ICS-LABA therapy. The fluticasone/formoterol combination, delivered via pressurized metered-dose inhaler and available in three dose strengths, has demonstrated a good safety and tolerability profile in trials of up to 1 year. The efficacy of fluticasone/formoterol is greater than that of fluticasone or formoterol alone and noninferior to that of fluticasone/salmeterol and budesonide/formoterol in tightly controlled 8-12-week clinical trials. Advantages of the fluticasone/formoterol combination aerosol include rapid onset of bronchodilation, an attribute preferred by patients, and emission of a high fine-particle fraction that is consistent at different flow rates, which may aid consistency of delivery (given patient variability in inhalation maneuvers) and provide real-life benefits.

AB - A new combination inhaler containing fluticasone, a potent inhaled corticosteroid (ICS), and formoterol, a long-acting β-agonist (LABA) with rapid onset and sustained bronchodilator effect, has been approved for treatment of persistent asthma in patients ≥12 years of age requiring combination ICS-LABA therapy. The fluticasone/formoterol combination, delivered via pressurized metered-dose inhaler and available in three dose strengths, has demonstrated a good safety and tolerability profile in trials of up to 1 year. The efficacy of fluticasone/formoterol is greater than that of fluticasone or formoterol alone and noninferior to that of fluticasone/salmeterol and budesonide/formoterol in tightly controlled 8-12-week clinical trials. Advantages of the fluticasone/formoterol combination aerosol include rapid onset of bronchodilation, an attribute preferred by patients, and emission of a high fine-particle fraction that is consistent at different flow rates, which may aid consistency of delivery (given patient variability in inhalation maneuvers) and provide real-life benefits.

KW - anti-inflammatory

KW - asthma

KW - bronchodilator

KW - fluticasone propionate

KW - formoterol fumarate

KW - inhaled corticosteroid

KW - long-acting ß-agonist

U2 - 10.1586/17476348.2014.905914

DO - 10.1586/17476348.2014.905914

M3 - Article

VL - 8

SP - 275

EP - 291

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

IS - 3

ER -